Argentum Pharmaceuticals LLC v. Novartis Pharmaceuticals Corporation

 
DOCKET NO.
OP. BELOW
SUBJECT
Patent

Question(s) Presented

  1. “Did the Federal Circuit categorically and erroneously preclude redress for injured members of joint ventures in the pharmaceutical industry by only recognizing (1) the manufactu[r]ing partner in the joint venture, and (2) the partner applying for FDA marketing approval in the joint venture, as having demonstrable injury-in-fact for Article III standing?”
  2. “Did the Federal Circuit err by rejecting the Leahy-Smith American Invents Act’s statutory estoppel provisions as a basis to demonstrate injury-in-fact for Article III standing?”

Posts About this Case

Date
Proceedings and Orders
January 6, 2021
DISTRIBUTED for Conference of 1/22/2021.
January 14, 2021
Response Requested. (Due February 16, 2021)